Telix ASX TLX Breaking News & Current Commentary, page-3081

AI DYOR

here’s a focused analysis of how 18F-aluminium fluoride (18F-AlF) could enhance NET (neuroendocrine tumour) diagnostics and therapy—especially with potential crossover to brain cancers and robotic-assisted treatments:

How 18F-AlF Could Improve NET Diagnostics & Therapy

1. Improved Imaging Precision

• 18F has superior imaging resolution vs. 68Ga due to its lower positron energy and longer half-life (~110 min).

• AlFluor-labeled NET agents (like [18F]AlF-DOTA-TATE) offer:

  • Higher contrast and better spatial resolution

  • More stable and scalable synthesis than conventional 18F chelation routes

  • Potential to image smaller or less active lesions missed by 68Ga

2. Simplified Global Access

• Can be centrally produced in cyclotrons and distributed, unlike 68Ga which is more localised to generator sites.

• Supports shake-and-inject kits, potentially expanding access in regional or lower-resource hospitals.

Implications for Brain Cancer & Robotic Surgery

1. Enhanced Tumor Localization in the Brain

• Brain cancers are difficult to image due to:

  • Blood-brain barrier (BBB)

  • Small lesion size and close proximity to critical structures

• If ligands targeting NET-like receptors (e.g. SSTR2) in some gliomas or brain metastases are used:

  • [18F]AlF-labeled agents could enable clearer tumour margins

  • Better tumor-to-background ratio could guide neurosurgeons more precisely

2. Integration with Robotic Surgery & Radiation

• Detailed 3D imaging with 18F-AlF PET could:

  • Feed into robotic navigation systems (e.g., ROSA, Brainlab) to improve precision excision

  • Allow preoperative planning with fused PET/MRI for safer resection

  • Enable targeted radiation therapy by precisely mapping tumor spread, possibly enhancing alpha or beta therapy targeting

Future Potential

• Theranostics: If NET or brain cancer agents can be dual-labeled for diagnosis (18F) and therapy (e.g., 177Lu, 225Ac), AlFluor™ could streamline the pipeline.

• Expanded target development: Telix and others may develop new ligands optimized for AlFluor, improving outcomes in brainstem NETs, meningiomas, or even pituitary tumors.